Ipamorelin Dosage Guide

Ipamorelin is a pentapeptide (5 amino acids) that mimics the action of ghrelin by binding to the growth hormone secretagogue receptor (GHS-R) in the pituitary gland. Unlike other GH secretagogues such as GHRP-6, ipamorelin is highly selective and does not significantly increase cortisol, ACTH, or prolactin at standard research doses.

Studies have demonstrated that ipamorelin produces a dose-dependent increase in growth hormone release with a profile that closely mimics natural pulsatile GH secretion. This selectivity makes it one of the most widely studied GH-releasing peptides in preclinical research.

Ipamorelin dosing is typically weight-based, though fixed-dose protocols are commonly used in research:

The weight-based equivalent is approximately 1 mcg/kg per injection. Most protocols target 200–300 mcg per injection, administered 2–3 times daily for a total daily dose of 400–900 mcg.

Timing is critical with ipamorelin due to its mechanism of stimulating pulsatile GH release:

• First dose: Upon waking, on an empty stomach (fasting for at least 2 hours enhances GH release).
• Second dose: Post-workout or mid-afternoon, at least 2 hours after last meal.
• Third dose (if applicable): Before bed, at least 2 hours after last meal.

Cycling: Ipamorelin can be used for extended periods (12–16+ weeks) without significant desensitization. Standard cycling is 12–16 weeks on, 4 weeks off. Some protocols run continuously for up to 6 months.

Ipamorelin is supplied as a lyophilized powder:

• Step 1: Swab vial stoppers with alcohol.
• Step 2: For a 5 mg vial, add 2.5 mL BAC water to yield 2 mg/mL (200 mcg per 0.1 mL).
• Step 3: Direct the stream along the vial wall. Let dissolve naturally.
• Step 4: Gently swirl until clear. Do not shake.
• Step 5: Store at 2–8°C. Use within 28 days.

Administer subcutaneously into the abdominal fat pad using a 29–31 gauge insulin syringe. Ipamorelin is often stacked with CJC-1295 (no DAC) for synergistic GH release.

Ipamorelin is considered one of the safest GH secretagogues due to its receptor selectivity:

• 100–200 mcg/injection: Generally well-tolerated. Occasional transient head rush, mild water retention.
• 200–300 mcg/injection: Possible numbness/tingling in extremities (carpal tunnel-like symptoms from elevated GH). Mild hunger increase.
• 300+ mcg/injection: Increased water retention, joint stiffness, possible transient hypoglycemia if injected in a fasted state.

Ipamorelin is for research purposes only and has not received FDA approval for any indication.

Do not use in subjects with active malignancies, as elevated GH/IGF-1 may promote tumor growth. Monitor blood glucose levels, particularly in insulin-resistant subjects. Consult a healthcare provider before initiating any peptide research protocol.